Cart
sales@molnova.com
Girentuximab
Girentuximab
Catalog No. M36663
Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP).
| Size | Price / USD | Stock | Quantity |
| 5MG | 558 | In Stock |
|
| 10MG | 896 | In Stock |
|
| 100MG | 2353 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGirentuximab
-
Brief Description
-
Description
-
Storage
-
NoteResearch use only, not for human use.
-
Reference1. Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920. ?
molnova catalog
related products
-
Benzolamide
Benzolamide inhibits carbonic anhydrase effectively and low-threshold calcium currents in hippocampal pyramidal neurons.
-
Histone acetyltransf...
Histone acetyltransferase p300 Inhibitor 4c is a 2-aminothiazole derivative. Histone acetyltransferase p300 Inhibitor 4c inhibited hCA I, hCA II, AChE and BChE with Ki values of 0.008 ± 0.001, 0.124 ± 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM. 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM.
-
Disulfamide
Disulfamide is an orally active carbonic anhydrase inhibitor with an IC50 value of 0.07 μM. Disulfamide has a diuretic effect by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal convoluted tubules.
